A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection

We acknowledge the Francis Crick Advanced Sequencing Facility, and Bioinformatics and Biostatistics Science Technology Platforms for their contribution to our sequencing processing. We acknowledge the NIHR Leicester Biomedical Research Centre for their support of the study at Leicester. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We thank the patients for their participation. We thank Asmaà Fritah-Lafont for help in co-ordinating the meetings regarding the study. We thank Dr. Lúcia Moreira-Teixeira for reviewing the manuscript and for the valuable discussion. A.O.G., C.M.G., and A.S. were funded by The Francis Crick Institute (Crick 10126; Crick 10468), which receives its core funding from Cancer Research UK, the UK Medical Research Council and the Wellcome Trust; and the sequencing project by the BIOASTER Microbiology Technology Institute, Lyon, France; Medical Diagnostic Discovery Department, bioMérieux SA, Marcy l’Etoile, France; and funded in part by Illumina Inc., San Diego, CA, USA. R.V. and J.L., University of Leicester, were funded by BIOASTER Microbiology Technology Institute, Lyon, France. This work has received, through BIOASTER investment, the funding from the French Government through the Investissement d’Avenir program (Grant No. ANR-10-AIRT-03). R.J.W. was supported by The Francis Crick Institute (Crick 10128), which receives its core funding from Cancer Research UK, the UK Medical Research Council and Wellcome; by Wellcome (104803; 203135); MRC South Africa under strategic health innovation partnerships; and NIH 019 AI 111276.